Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.
Stern, Anat; Carrara, Elena; Bitterman, Roni; Yahav, Dafna; Leibovici, Leonard; Paul, Mical.
Cochrane Database Syst Rev
; 1: CD012184, 2019 Jan 03.
Artigo em Inglês | MEDLINE | ID: mdl-30605229
Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.
Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.
Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.
Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases.
Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis.
Association between adherence to an antimicrobial stewardship program and mortality among hospitalised cancer patients with febrile neutropaenia: a prospective cohort study.
Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
Can complications in febrile neutropenia be predicted? Report from a developing country.
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia.